# nature portfolio

Corresponding author(s):

Last updated by author(s):

Shu-JungChang

Mar.19th,2024

# Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Please do not completeany field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

#### **Statistics**

For all statistical analyses, confirm that the following items are present in the figurelegend, table legend, main text, or Methods section.				
n/a	/a Confirmed			
	$\boxtimes$	The exact sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement		
	$\boxtimes$	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly $% \mathcal{L}_{\mathcal{A}}$		
		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.		
$\boxtimes$		A description of all covariates tested		
	$\boxtimes$	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates(e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
		For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.		
$\boxtimes$		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings		
$\boxtimes$		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
$\boxtimes$		${\sf Estimates}  of  {\sf effect sizes}  ({\sf e.g.  Cohen's  d}, {\sf Pearson's  r}),  {\sf indicating  how  they  were  {\sf calculated}}$		
	1	Ourweb collection on statistics for biologists contains articles on many of the points above.		

#### Software and code

Policy information about <u>availability of computer code</u>

Datacollection	CFX Manager™ Software (gene expression), ChemiDoc MP Imaging System and Image Lab (imaging and quantification of the band intensity of western blot), Canvas X Draw & Adobe Photoshop (image preparation), FlowJo (analysis of flow cytometry data), CLC Genomics and MSigDB (RNA-seq analysis), BioRender.
Dataanalysis	Statistic calculations were performed using GraphPad Prism V9. Images were processed and rendered by Image J (Fiji), Imaris (Oxford) or Zen-blue edition (Zeiss).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

- All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
  - Accession codes, unique identifiers, or web links for publicly available datasets
  - A description of any restrictions on data availability
  - For clinical datasets or third party data, please ensure that the statement adheres to our policy

The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE247045. Source data are provided with this paper.

# nature portfolio | reporting summary

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Ecological, evolutionary & environmental sciences Behavioural & social sciences

🔀 Lifesciences Forareferencecopy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

### Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Samplesize	Sample size was determined based on references or experiences.
Dataexclusions	Nodata was excluded.
Replication	At least three independent experiments were performed with similar results. The number (n) of biological replicates were indicated in the figure legends.
Randomization	In all cases, samples (animals, cultured cell lines, etc) were randomly assigned to the different experimental groups.
Blinding	N/A

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

#### Materials & experimental systems

Palaeontology and archaeology

Animals and other organisms

Dual use research of concern

n/a Involved in the study

Antibodies

Eukaryotic cell lines

Clinical data

Plants

 $\boxtimes$ 

 $\boxtimes$ 

 $\boxtimes$ 

	Met	hods
_	n/a	Involved in the study

- ChIP-seq  $\boxtimes$
- Flow cytometry  $\boxtimes$ MRI-based neuroimaging

#### Antibodies

 $\boxtimes$  $\boxtimes$ 

Antibodiesused	
Antibodicsuscu	Rabbit anti-ATF3; Abcam; Cat #: ab207434
	Rabbit anti-COXIV; Cell Signaling; Cat #: 4850
	Rabbit anti-TFAM; Cell Signaling; Cat #: 8076
	Rabbit anti-p16INK4A; Cell Signaling; Cat #: 80772
	Mouse anti-dsDNA; Abcam; Cat #: ab27156
	Rabbitanti-phospho-elF2α(Ser51);CellSignaling;Cat#:3398
	Rabbit anti-eIF2α; Cell Signaling; Cat #: 5324
	Rabbitanti-p44/42 MAPK(Erk1/2);Cell Signaling;Cat #: 4695
	Rabbitanti-phospho- p44/42 MAPK(Erk1/2) (Thr202/Tyr204); Cell Signaling; Cat #: 4370
	Rabbit anti-GCN2;Cell Signaling; Cat #: 65981
	Rabbit anti-GCN2 (phosphos T899); Abcam; Cat #: ab75836
	Mouse anti-SAPK/JNK(Thr183/Tyr185); Cell signaling; Cat #:9255
	Rabbit anti-SAPK/JNK; Cell Signaling; Cat #: 9252
	Mouse anti-p38α; Cell Signaling; Cat #: 9217
	Rabbit anti-phosphop38 MAPK (Thr180/Tyr182); Cell Signaling; Cat #: 4511
	Rabbit anti-NF-ĸBp65; Cell Signaling; Cat #: 8242
	Rabbit anti-phospho-NF-kB p65 (Ser536); Cell Signaling; Cat #: 3033
	Mouse anti-TOMM20; Santa Cruz; Cat #: sc-17764
	Rabbit anti-PERK; Cell signaling; Cat #: 5683
	Rabbit anti-PKR (phosphor T446); Cell signaling; Cat #: ab32036
	Mouse anti-PKR; Santa Cruz; Cat #: sc-6282
	Rabbitanti-phosphoTBK-1/NAK (Ser172); Cell signaling; Cat #: 5483
	Rabbit anti-TBK-1/NAK; Cellsignaling; Cat #: 3504
	Anti-mouse IgG, HRP-linked antibody; Cell signaling; Cat #: 7076
	Anti-rabbit IgG, HRP-linked antibody; Cell signaling; Cat #: 7074
	StarBright Blue 700 goat anti-rabbit IgG; Bio-Rad; Cat #: 12004161
	Peroxidase AffiniPure goat anti-mouse IgG (H+L); The Jackson Laboratory; Cat #: 115035003
	Peroxidase AffiniPure goat anti-rabbit IgG (H+L); The Jackson Laboratory; Cat #: 111035003
	Mouse anti-γH2AX; Merck Millipore; Cat #: 05636
	Rabbit anti-yH2AX; Abcam; Cat #: ab11175
	Rabbit anti-β-actin; ABclonal; Cat #: AC026
	DAPI; Sigma-Aldrich; Cat #: D9542
	Rabbitanti-GADD153; GeneTex; Cat #: GTX112827
	Rabbit anti-STING; Cell signaling; Cat #: 13647
	Rabbit anti-cGAS; Cell signaling; Cat #: 15102
	Rabbit anti-p53; Cell signaling; Cat #: 9282
	Normal mouse IgG; Santa Cruz; Cat #: sc-2025
	Goat anti-rabbit IgG (H+L) cross absorbed secondary antibody, Biotin-XX; Thermo Fisher; Cat #: B2770
	6x-His Tag Monoclonal Antibody; Thermo Fisher; Cat #: 21315

#

Mouse Phospho-p53; Cell signalin Rabbit anti-p21; Cell signaling; Cat	
1 , 0 0,	
Rabbitanti-AIM2;GeneTex;Cat#:	
Rabbitanti-ATM; GeneTex; Cat#:	
Mouse anti-CD16/32; BioLegend;	
Mouse anti-Caspase 9; Cell signali	
Mouse anti-NLRP3; AdipoGen; Ca	
Mouse anti-CD289 (TLR9) FITC; eE	
InVivoMAb anti-mouse CD3ε (145	
InVivoMAb anti-mouse CD28 (37.5	
Goat Anti-Mouse Ig (H+L); Souther	
APC/FireTM 750 anti-mouse CD4;	
anti-GSDMD; Cell signaling; Cat #: !	
PE Anti-mouse Granzyme B (NGZE	
Alexa Fluor 700 anti- mouse CD8a	; BD Pharmingen; Cat #: 557959
PE/Dazzle anti-mouse IFN-g (XMG	1.2); Biolegend; Cat #: 505845
FITC anti-mouse CD28 (E18); Biole	gend; Cat #: 122007
APC anti-mouse TIGIT (1G9); Biole	gend; Cat #: 142105
Brilliant Violet 605 anti-mouse/hu	man KLRG-1 (2F1/KLRG1); Biolegend; Cat #: 138419
Rabbit anti-phospho STING (Ser 36	6); Cell signaling; Cat #: 50907
Streptavidin, Alexa Flour 568 conj	ugate; Thermo Fisher; Cat #: S11226
Goat anti-Mouse IgG1 Cross-Ads	orbed Secondary Antibody, Alexa Fluor™ 594; Invitrogen; Cat#: A-21125
Goat anti-Rabbit IgG (H+L) Highly	y Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488; Invitrogen; Cat#: A-11034
Goat anti-Rabbit IgG (H+L) Highly	y Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 647; invitrogen; Cat#: A-11012
Goat anti-Rabbit IgG (H+L) Cross	-Adsorbed Secondary Antibody, Alexa Fluor™ 594; invitrogen; Cat#: A-11012
	y Cross-Adsorbed Secondary Antibody, Alexa Fluor™ Plus 647; Invitrogen; Cat#: A-32728
Goat anti-Mouse IgG1 Cross-Ads	orbed Secondary Antibody, Alexa Fluor™ 488; Invitrogen; Cat#: A-21121

Validation

All antibodies were purchased from reputable vendors and validated with positive or negative control in this study. Commercial antibodies were also validated by the manufacturers as stated in the manual instructions.

#### Eukaryotic cell lines

Policy information about <u>cell lines and Sex and Gender in Research</u>				
Cell line source(s)	Henle-407 originally obtained from the Roy Curtiss laboratory collection, were provided as a gift from Dr. Jorge Galan's lab. THP-1ATCC TIB-202, RAW 264.7 ATCC TIB-71			
Authentication	Cell lines were not authenticated			
Mycoplasmacontamination	The cell lines were routinely tested with Mycoplasma.			
Commonlymisidentifiedlines (See <u>ICLAC</u> register)	N/A			

#### Animals and other organisms

vinformation about studies			

Laboratoryanimals	Six-to eight-week-old, sex-matched and wild-type C57BL/6 mice were used in related experiments.
Wildanimals	N/A
Field-collectedsamples	N/A
Ethicsoversight	All animal experiments were conducted in strict accordance with the protocols approved by the policies of the National Taiwan University College of Medicine

Note that full information on the approval of the study protocol must also be provided in the manuscript.

#### Flow Cytometry

#### Plots

#### Confirmthat:

The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

Samplepreparation	All protocols of the FACS related experiments are described in detail in the "Methods" section. Typically, the FACS experiments involved staining with one to two colors, unless explicitly specified otherwise.
Instrument	Flow data was obtained by FACSCalibur Flow Cytometer (BD Biosciences)
Software	Data were analyzed with Flowjo V10.8.1.
Cell populationabundance	Primary murine CD8/CD4 T cells, THP-1 and Henle-407 cells

THP-1 and Henle-407 nonulations were identified with FSC-H/SSC-H. The gating strategies of CD4/CD8T cell related experiments were

Gatingstrategy

 $\boxtimes$  Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information